Qiang Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiang Wan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Hao Zhang
Clinical Medical College, Jiangxi University of Chinese Medicine
6 shared publicationsZhongyong Liu
Clinical Medical College, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China
5 shared publicationsChengyan Guan
Graduate School of Jiangxi University of Chinese Medicine, Nanchang 330004, China
4 shared publicationsHaoyue Jia
Clinical Medical College, Jiangxi University of Chinese Medicine
4 shared publicationsMing Yang
Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
4 shared publicationsJianguang Wu
Department of Medical Cardiology, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1927210
Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential
Atherosclerosis, the principal pathological underpinning of cardiovascular diseases, is a multifaceted process encompassing dysregulated lipid metabolism, chronic inflammation, oxidative stress, aberrant vascular smooth muscle cells (VSMCs) proliferation, and plaque destabilization. Lipocalin-2 (LCN-2), a pivotal member of the lipocalin superfamily, serves as a critical nexus integrating lipid metabolism with inflammatory cascades. This review systematically delineates the gene localization, protein architecture, and expression regulation of LCN-2, with a focus on its multifaceted roles and molecular mechanisms across diverse stages of atherosclerosis, including endothelial dysfunction, lipid deposition, inflammatory amplification, foam cell formation, VSMCs phenotypic switching, and plaque rupture. This work highlights the promise of LCN-2 as a diagnostic biomarker and therapeutic target, offering novel insights and strategic directions for the precise prevention and management of atherosclerosis. Given its pathogenic significance, elevated LCN-2 levels in serum, plasma, urine, and plaque tissue serve as diagnostic and prognostic biomarkers for atherosclerosis. Multiple therapeutic strategies targeting LCN-2, including gene knockout, neutralizing antibodies, small-molecule inhibitors, RNA interference and repurposed clinical drugs, have achieved encouraging anti-atherosclerotic effects in preclinical studies. Collectively, LCN-2 acts as a core molecular linker between inflammation and lipid metabolism in atherosclerosis, and targeting LCN-2 holds great potential for the early diagnosis, risk stratification and novel therapeutic intervention of atherosclerotic cardiovascular diseases.
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1927210
Open AccessTargeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential
Atherosclerosis, the principal pathological underpinning of cardiovascular diseases, is a multifaceted process encompassing dysregulated lipid metabolism, chronic inflammation, oxidative stress, aberrant vascular smooth muscle cells (VSMCs) proliferation, and plaque destabilization. Lipocalin-2 (LCN-2), a pivotal member of the lipocalin superfamily, serves as a critical nexus integrating lipid metabolism with inflammatory cascades. This review systematically delineates the gene localization, protein architecture, and expression regulation of LCN-2, with a focus on its multifaceted roles and molecular mechanisms across diverse stages of atherosclerosis, including endothelial dysfunction, lipid deposition, inflammatory amplification, foam cell formation, VSMCs phenotypic switching, and plaque rupture. This work highlights the promise of LCN-2 as a diagnostic biomarker and therapeutic target, offering novel insights and strategic directions for the precise prevention and management of atherosclerosis. Given its pathogenic significance, elevated LCN-2 levels in serum, plasma, urine, and plaque tissue serve as diagnostic and prognostic biomarkers for atherosclerosis. Multiple therapeutic strategies targeting LCN-2, including gene knockout, neutralizing antibodies, small-molecule inhibitors, RNA interference and repurposed clinical drugs, have achieved encouraging anti-atherosclerotic effects in preclinical studies. Collectively, LCN-2 acts as a core molecular linker between inflammation and lipid metabolism in atherosclerosis, and targeting LCN-2 holds great potential for the early diagnosis, risk stratification and novel therapeutic intervention of atherosclerotic cardiovascular diseases.
- 2 January 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 122, 108877
Mechanistic insights into cardiovascular toxicity induced by polycyclic aromatic hydrocarbons using Benzo[a]pyrene (BaP) as an example
- 2 January 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 122, 108877
Mechanistic insights into cardiovascular toxicity induced by polycyclic aromatic hydrocarbons using Benzo[a]pyrene (BaP) as an example
- 7 August 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 441, 133737
Letter regarding the study by Nilsen et al. on IL-1RA and 5-year mortality risk: Redefining the threshold for high admission levels of IL-1RA
- 7 August 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 441, 133737
Letter regarding the study by Nilsen et al. on IL-1RA and 5-year mortality risk: Redefining the threshold for high admission levels of IL-1RA
- Open Access
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1620152
Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases
Cardiovascular diseases (CVDs) have emerged as one of the leading causes of global mortality and health burden, with their prevalence and mortality rates demonstrating a persistent upward trend, thereby posing significant challenges to public health worldwide. Tanshinone IIA (Tan IIA), the principal lipophilic bioactive component isolated from Salvia miltiorrhiza Bunge, has gained substantial recognition in cardiovascular therapeutics. Accumulating evidence from recent investigations has demonstrated that Tan IIA exhibits multi-target pharmacological properties and modulates diverse signaling pathways in cardiovascular protection, positioning it as a promising candidate in natural product-based drug discovery. The therapeutic efficacy is mediated through multiple mechanisms, including but not limited to anti-atherosclerotic effects, lipid homeostasis regulation, anti-arrhythmic properties, myocardial functional enhancement, and hemodynamic stabilization. This comprehensive review systematically elucidates the molecular mechanisms and therapeutic targets underlying Tan IIA’s cardio-protective effects, particularly focusing on its anti-inflammatory, antioxidant, anti-atherosclerotic, and myocardial preservation properties. Furthermore, we critically evaluate its current clinical applications and propose potential directions for future research to optimize its therapeutic potential in cardiovascular medicine.
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1620152
Open AccessHarnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases
Cardiovascular diseases (CVDs) have emerged as one of the leading causes of global mortality and health burden, with their prevalence and mortality rates demonstrating a persistent upward trend, thereby posing significant challenges to public health worldwide. Tanshinone IIA (Tan IIA), the principal lipophilic bioactive component isolated from Salvia miltiorrhiza Bunge, has gained substantial recognition in cardiovascular therapeutics. Accumulating evidence from recent investigations has demonstrated that Tan IIA exhibits multi-target pharmacological properties and modulates diverse signaling pathways in cardiovascular protection, positioning it as a promising candidate in natural product-based drug discovery. The therapeutic efficacy is mediated through multiple mechanisms, including but not limited to anti-atherosclerotic effects, lipid homeostasis regulation, anti-arrhythmic properties, myocardial functional enhancement, and hemodynamic stabilization. This comprehensive review systematically elucidates the molecular mechanisms and therapeutic targets underlying Tan IIA’s cardio-protective effects, particularly focusing on its anti-inflammatory, antioxidant, anti-atherosclerotic, and myocardial preservation properties. Furthermore, we critically evaluate its current clinical applications and propose potential directions for future research to optimize its therapeutic potential in cardiovascular medicine.
- Open Access
- 25 April 2025
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 17  (3) , 464-472
Research progress of regulating intestinal flora by traditional Chinese medicine in treating coronary heart disease
- 25 April 2025
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 17  (3) , 464-472
Open AccessResearch progress of regulating intestinal flora by traditional Chinese medicine in treating coronary heart disease
- Open Access
- 20 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (1) , e0314298
Higher magnesium depletion score increases the risk of all‑cause and cardiovascular mortality in US adults with diabetes
Background: Both dietary magnesium and serum magnesium are associated with the prognosis of diabetic patients. However, the impact of the magnesium depletion score (MDS), which assesses systemic magnesium deficiency, on the prognosis of diabetic patients remains unclear. This cohort study aims to explore the potential association between the MDS and all-cause and cardiovascular mortality in diabetic patients. Methods: In this study, we analyzed data from 5,219 diabetic individuals from National Health and Nutrition Examination Survey (NHANES) 2003–2018. Participant mortality information was sourced from the National Death Index records. MDS was divided into lower MDS (0–1 points), middle MDS (2 points), and higher MDS (3–5 points) groups. Weighted multivariable Cox regression was utilized to explore the potential association between MDS and mortality in diabetic patients. Stratified analyses and sensitivity analyses were employed to validate the robustness of our findings. Results: Among the 5,219 participants included in this study, 1,212 experienced all-cause mortality, and 348 experienced cardiovascular mortality. Weighted multivariable Cox regression indicated that higher MDS was strongly linked to a heightened risk of mortality in all models, including the fully adjusted model (all-cause mortality: HR = 1.58, 95% CI: 1.20–2.08; cardiovascular mortality: HR = 1.92, 95% CI: 1.28–2.88). In the stratified analysis, we found that the association between MDS and all-cause mortality was stronger among individuals aged <60 years. No significant differences were found in the relationship between MDS and mortality within other subgroups. In the sensitivity analyses, our results remained robust. Conclusions: An increase in MDS is significantly correlated with a higher risk of all-cause and cardiovascular mortality in diabetic patients. The risk of all-cause mortality was higher in diabetic patients aged <60. Early monitoring and management of MDS, as well as optimizing magnesium nutritional status, may benefit diabetic patients.
- 20 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (1) , e0314298
Open AccessHigher magnesium depletion score increases the risk of all‑cause and cardiovascular mortality in US adults with diabetes
Background: Both dietary magnesium and serum magnesium are associated with the prognosis of diabetic patients. However, the impact of the magnesium depletion score (MDS), which assesses systemic magnesium deficiency, on the prognosis of diabetic patients remains unclear. This cohort study aims to explore the potential association between the MDS and all-cause and cardiovascular mortality in diabetic patients. Methods: In this study, we analyzed data from 5,219 diabetic individuals from National Health and Nutrition Examination Survey (NHANES) 2003–2018. Participant mortality information was sourced from the National Death Index records. MDS was divided into lower MDS (0–1 points), middle MDS (2 points), and higher MDS (3–5 points) groups. Weighted multivariable Cox regression was utilized to explore the potential association between MDS and mortality in diabetic patients. Stratified analyses and sensitivity analyses were employed to validate the robustness of our findings. Results: Among the 5,219 participants included in this study, 1,212 experienced all-cause mortality, and 348 experienced cardiovascular mortality. Weighted multivariable Cox regression indicated that higher MDS was strongly linked to a heightened risk of mortality in all models, including the fully adjusted model (all-cause mortality: HR = 1.58, 95% CI: 1.20–2.08; cardiovascular mortality: HR = 1.92, 95% CI: 1.28–2.88). In the stratified analysis, we found that the association between MDS and all-cause mortality was stronger among individuals aged <60 years. No significant differences were found in the relationship between MDS and mortality within other subgroups. In the sensitivity analyses, our results remained robust. Conclusions: An increase in MDS is significantly correlated with a higher risk of all-cause and cardiovascular mortality in diabetic patients. The risk of all-cause mortality was higher in diabetic patients aged <60. Early monitoring and management of MDS, as well as optimizing magnesium nutritional status, may benefit diabetic patients.
- Open Access
- 26 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 179
Protective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms
- 26 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 179
Open AccessProtective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms
- Open Access
- 2 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103  (31) , e39104
Exploring therapeutic targets and molecular mechanisms for treating diabetes mellitus-associated heart failure with Qishen Yiqi dropping pills: A network pharmacology and bioinformatics approach
Diabetes mellitus (DM) and heart failure frequently coexist, presenting significant public health challenges. QiShenYiQi Dropping Pills (QSDP) are widely employed in the treatment of diabetes mellitus concomitant with heart failure (DM-HF). Nevertheless, the precise mechanisms underlying their efficacy have yet to be elucidated. Active ingredients and likely targets of QSDP were retrieved from the TCMSP and UniProt databases. Genes associated with DM-HF were pinpointed through searches in the GeneCards, OMIM, DisGeNET, and TTD databases. Differential genes connected to DM-HF were sourced from the GEO database. Enrichment analyses via gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways, as well as immune infiltration assessments, were conducted using R software. Further analysis involved employing molecular docking strategies to explore the interactions between the identified targets and active substances in QSDP that are pertinent to DM-HF treatment. This investigation effectively discerned 108 active compounds and 257 targets relevant to QSDP. A protein–protein interaction network was constructed, highlighting 6 central targets for DM-HF treatment via QSDP. Gene ontology enrichment analysis predominantly linked these targets with responses to hypoxia, metabolism of reactive oxygen species, and cytokine receptor interactions. Analysis of Kyoto Encyclopedia of Genes and Genomes pathways demonstrated that these targets mainly participate in pathways linked to diabetic complications, such as AGE-RAGE signaling, dyslipidemia, arteriosclerosis, the HIF-1 signaling pathway, and the tumor necrosis factor signaling pathway. Further, immune infiltration analysis implied that QSDP’s mechanism in treating DM-HF might involve immune-mediated inflammation and crucial signaling pathways. Additionally, molecular docking studies showed that the active substances in QSDP have strong binding affinities with these identified targets. This research presents a new model for addressing DM-HF through the use of QSDP, providing novel insights into incorporating traditional Chinese medicine (TCM) principles in the clinical treatment of DM-HF. The implications of these findings are substantial for both clinical application and further scientific inquiry.
- 2 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103  (31) , e39104
Open AccessExploring therapeutic targets and molecular mechanisms for treating diabetes mellitus-associated heart failure with Qishen Yiqi dropping pills: A network pharmacology and bioinformatics approach
Diabetes mellitus (DM) and heart failure frequently coexist, presenting significant public health challenges. QiShenYiQi Dropping Pills (QSDP) are widely employed in the treatment of diabetes mellitus concomitant with heart failure (DM-HF). Nevertheless, the precise mechanisms underlying their efficacy have yet to be elucidated. Active ingredients and likely targets of QSDP were retrieved from the TCMSP and UniProt databases. Genes associated with DM-HF were pinpointed through searches in the GeneCards, OMIM, DisGeNET, and TTD databases. Differential genes connected to DM-HF were sourced from the GEO database. Enrichment analyses via gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways, as well as immune infiltration assessments, were conducted using R software. Further analysis involved employing molecular docking strategies to explore the interactions between the identified targets and active substances in QSDP that are pertinent to DM-HF treatment. This investigation effectively discerned 108 active compounds and 257 targets relevant to QSDP. A protein–protein interaction network was constructed, highlighting 6 central targets for DM-HF treatment via QSDP. Gene ontology enrichment analysis predominantly linked these targets with responses to hypoxia, metabolism of reactive oxygen species, and cytokine receptor interactions. Analysis of Kyoto Encyclopedia of Genes and Genomes pathways demonstrated that these targets mainly participate in pathways linked to diabetic complications, such as AGE-RAGE signaling, dyslipidemia, arteriosclerosis, the HIF-1 signaling pathway, and the tumor necrosis factor signaling pathway. Further, immune infiltration analysis implied that QSDP’s mechanism in treating DM-HF might involve immune-mediated inflammation and crucial signaling pathways. Additionally, molecular docking studies showed that the active substances in QSDP have strong binding affinities with these identified targets. This research presents a new model for addressing DM-HF through the use of QSDP, providing novel insights into incorporating traditional Chinese medicine (TCM) principles in the clinical treatment of DM-HF. The implications of these findings are substantial for both clinical application and further scientific inquiry.
- Open Access
- 18 October 2021
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 227, 112912
Urban fine particulate air pollution exposure promotes atherosclerosis in apolipoprotein E-deficient mice by activating perivascular adipose tissue inflammation via the Wnt5a/Ror2 signaling pathway
- 18 October 2021
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 227, 112912
Open AccessUrban fine particulate air pollution exposure promotes atherosclerosis in apolipoprotein E-deficient mice by activating perivascular adipose tissue inflammation via the Wnt5a/Ror2 signaling pathway
- 1 January 2021
- Published by Elsevier in Life Sciences
- Vol. 264, 118715
Ambient fine particulate matter aggravates atherosclerosis in apolipoprotein E knockout mice by iron overload via the hepcidin-ferroportin axis
- 1 January 2021
- Published by Elsevier in Life Sciences
- Vol. 264, 118715
Ambient fine particulate matter aggravates atherosclerosis in apolipoprotein E knockout mice by iron overload via the hepcidin-ferroportin axis